A number of previously fatal neurological conditions have been rendered treatable, chronic conditions by advances in research. As clinicians delivering a diagnosis such as Parkinson's disease (PD) to a concerned patient, we take solace in the knowledge that we have many symptomatic therapies to restore quality of life. Just as we consider the individual's pertinent symptoms and comorbidities in selecting treatments, we must also consider the prevalence and impact of medication nonadherence. Previously referred to as medication compliance, the term "medication adherence" is preferred as it emphasizes patient autonomy and decision-making [1, 2] .
fraught with potential error, the commonest practically used measure is provider judgment, which has a sensitivity of 10-40 % [7, 8] . Estimates of nonadherence prevalence in PD range widely, from 15-20 % by self-report to 67 % and higher in studies using pharmacy refill data and pill counts [9, 10] .
A comparison of different measures of adherence in PD found that self-report and simple pill count both grossly underestimated nonadherence, explaining some of the variability in the estimates of prevalence [11] . This situation is further complicated in PD by the concept of timing adherence: does the patient take dopaminergic medications at evenly spaced intervals as prescribed, or erratically when he or she remembers a forgotten dose? The not-uncommon patient who takes dopaminergic medications three times per day may interpret the instructions to suggest three pills should be taken at once, three doses should be taken within several hours of each other, or doses should be taken immediately on waking and before bedtime with a third dose taken sometime in between. Such timing nonadherence contributes to unwanted pulsatile dopamine variability, implicated in the earlier development of motor fluctuations [12] .
Viewing nonadherence through the lens of PD brings many of the pertinent factors into focus. First, polypharmacy is exceedingly common, with over half of patients taking at least two antiparkinsonian drugs in addition to multiple prescriptions for nonmotor manifestations and other comorbidities [13] . This is likely an underestimate given the more widespread use of dopamine agonists and the introduction of rasagiline since the publication of the previous study [13] . Furthermore, dopaminergic drugs are often taken three to four times daily, with advanced PD patients taking as many as six to ten doses per day. Greater regimen complexity is strongly correlated with nonadherence in PD [14, 15] . This is consistent with the findings of a systematic review of chronic diseases in which adherence was highest for once-daily formulations, dropping off sharply with each additional daily dose [16] .
Depression has been identified as an independent risk factor for nonadherence and a common nonmotor manifestation of PD. Studies in depressed populations have found a threefold increase in nonadherence with all prescribed medications [17] , and a single-center study found nonadherence was associated with worse depression and poorer quality of life in PD specifically [15] . Although these studies demonstrate strong associations between depression and nonadherence, causation remains elusive to prove. Depression may fuel nonadherence and vice versa. Given the 30-40 % prevalence of depression in PD [18] , depression is likely a significant potential contributor to nonadherence in this patient population. Existing evidence that depression has the most impact on PD patients' health-related quality of life [19] combined with data regarding the effect of depression on nonadherence suggests that interventions targeting improved antidepressant adherence could have a significant impact on both motor and nonmotor symptoms as well. However, no studies have evaluated antidepressant therapy adherence in PD.
Cognitive impairment is another common feature of PD and a contributor to nonadherence. At least 30-40 % of PD patients meet the criteria for dementia, with estimates of up to 78 % in studies of cumulative prevalence [20] . In particular, impairments in executive function and working memory are common in PD and have been independently associated with medication nonadherence [21, 22] . Additional factors associated with nonadherence include lack of social support [15] , nonmodifiable demographic and educational factors [1] , low health literacy [23] , and the cost of medications [24] .
The individual patient's beliefs and expectations regarding medications certainly play a critical role in medication-taking behavior, although this remains relatively unexplored in the PD population [9] . Nonadherent individuals are more likely to report being undertreated, refuting the notion that nonadherence is in response to the perception of being overmedicated [11] . A separate study found no difference in prior adverse events experienced by PD patients with and without satisfactory adherence [15] . These findings suggest that not just the physician, but also the patient, notes suboptimally controlled symptoms and incorrectly ascribes them to undertreatment or disease progression. In turn, medication doses or frequencies are increased, drug regimens are changed, or the diagnosis itself is questioned, leading to additional diagnostic testing, patient stress, and further nonadherence [9] .
Consequences of nonadherence include worse disease control, with diminished mobility, greater fluctuations, dyskinesias, and worsening quality of life. In a multicenter European study, suboptimal adherence in PD was associated with marked differences in the prescribed doses versus the doses taken, with poor adherers being prescribed a median of 765 mg of levodopa daily and taking an average of 481 mg less than prescribed, compared with satisfactory adherers being prescribed 400 mg and underusing by only 8 mg [25] . A similar relationship held for dopamine agonists. In the same multicenter study, suboptimal adherence was significantly associated with higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores (median 29, interquartile range 20-40) compared with satisfactory adherers (median 19, interquartile range 13-26), without a higher rate of adverse events in the suboptimally adherent group to explain the underuse. This study also found the greatest adherence for once-daily drugs, recapitulating the findings from other chronic conditions. The relationship between suboptimal adherence, higher medication doses, and worsening disability has been replicated in additional PD populations [9] . This is consistent with the theory that suboptimal disease control due to nonadherence is interpreted by physicians as requiring uptitration of medications, leading to greater disparities between prescribed and administered doses.
The impact of nonadherence in PD extends beyond the individual patient. A recent study of PD patients within a national database of US managed care plans found that nonadherers had significantly higher rates of yearly hospitalizations (2.3 vs 1.8), office visits, and ancillary care visits, with higher total medical costs ($15,826 vs $9,228) despite lower prescription drug costs. Adjustment for confounders, including comorbidity burden, resulted in nonadherence being associated with a $3,451 yearly increase in medical costs [10] .
Although the ramifications of nonadherence are considerable, evidence-based approaches to remedying the situation are sparse. The heterogeneity of conditions and contributing factors studied, the number and types of interventions applied, and limited follow-up of outcomes characterize the approaches to date. A recent Cochrane review of interventions Electronic monitoring caps on all PD drugs
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NA not available across numerous medical conditions found only a small number to have a statistically significant impact on short-term and long-term adherence, with improvement in treatment outcomes being even less common [2] . The following interventions were studied [2] : Of the successful interventions, most were complex combinations of increased follow-up, regimen simplification, mailed and telephoned reminders or reinforcement, counseling, and supportive care. Despite the sweeping scale and cost of such programs, the clinical impact remained marginal.
In PD specifically, one study compared targeted verbal and written patient education on the continuous dopaminergic theory with usual care. Electronic medication monitoring devices assessed adherence to medication timing before and after the educational intervention [12] . At the baseline, only 17-21 % of all medications were taken at the appropriate time interval, with a statistically significant increase to 39 % of all doses in the active group after intervention. There were no statistically significant differences between quality-of-life scores, UPDRS motor scores, or adverse events between groups. The study was limited by short follow-up and substantial attrition in both groups. A second, ongoing study is evaluating a brief form of cognitive-behavioral therapy focused on medication adherence in patients with PD and their caregivers [26] . This study, too, is limited by a short duration of planned follow-up, and the assessment of medication adherence by a surrogate marker rather than a gold standard.
These findings have broad implications for research and practice. Further inquiry is necessary to explore the patient characteristics, beliefs, and decision-making processes associated with medication nonadherence. These investigations should include electronic medication monitoring caps-considered the gold-standard measure of adherence [27] -and account for the frequent involvement of care partners in the PD population. Although pill counting is frequently used to assess adherence in clinical trials, it fails to capture timing nonadherence, and in daily practice it relies on patients bringing all of their medications to clinic visits and places a time-consuming burden on practitioners. Interventions that incorporate disease-specific, plainlanguage patient education, motivational counseling, and new technology should be rigorously studied for their impact on health outcomes, including UPDRS scores and quality-of-life measures. Studies must be appropriately powered to find such outcomes, in terms of both adequate recruitment and sufficient length of follow-up in the setting of a slowly progressive disease. Given the prevalence and consequences of comorbid affective disorders in PD, we must quantify the impact of antidepressant nonadherence and adopt successful interventions. Likewise, substantial evidence supports the use of physical therapy and exercise as part of the PD treatment regimen [28] ; however, adherence to these recommendations is also unknown. Finally, in an era of skyrocketing health care costs without commensurate gains in disease-free survival, any interventions must be evaluated for their impact on health care utilization and costeffectiveness.
As clinicians, we must recognize medication nonadherence as a common, underreported, detrimental, and costly cause of suboptimal disease control in PD. Our clinical judgment about nonadherence is demonstrably flawed, and we will not find what we do not sensitively seek. It is imperative that health care providers use nonjudgmental interviewing skills that allow a patient to admit to nonadherence without fear of disapproval or cessation of care. We should pursue the barriers to an individual's nonadherence and apply clinical resources to overcome them. This may be as simple as providing simple explanations of prescriptions, or as sweeping as nonadherence counseling provided by physician extenders and other health care providers. These steps should be a requisite action before any drug regimen is deemed ineffective, in order to avoid undue dose escalations, adverse effects, and increased costs to the individual patient and the health care system.
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